Supporting the idea about the existence of an impairment in TGF-β/SMAD signaling in progressive U-CLL cases, we found low expression of the kinase inhibitor p21−Cip1 and high expression of c-Myc compared with stable U-CLL. The gene discussed is CDKN1A; the disease is B-cell chronic lymphocytic leukemia.